Madrigal Pharmaceuticals: Rezdiffra Commercialization Bodes Well For Continued Growth

Group 1 - Brendan completed a Ph.D. in organic synthesis at Stanford University in 2009 and has a background in the pharmaceutical industry, having worked for Merck from 2009 to 2013 [1] - Brendan has experience in biotech startups, including Theravance and Aspira, and is a co-founder of 1200 Pharma, which received significant investment in the eight figures [1] - Brendan remains an avid investor with a focus on market trends, particularly in biotechnology stocks [1]